Free Trial
NASDAQ:TPST

Tempest Therapeutics Q1 2026 Earnings Report

Tempest Therapeutics logo
$1.27 +0.02 (+1.60%)
As of 02:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tempest Therapeutics EPS Results

Actual EPS
-$2.53
Consensus EPS
-$0.28
Beat/Miss
Missed by -$2.25
One Year Ago EPS
N/A

Tempest Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tempest Therapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Tempest Therapeutics' Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tempest Therapeutics Earnings Headlines

The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the world's largest fund managers - including a section naming one small company Musk's Colossus cannot operate without. Right now, most fund managers have never heard of it. By Friday, every one of them will. Dylan Jovine has identified the name and ticker before $75 billion in new capital starts chasing the SpaceX supply chain.tc pixel
See More Tempest Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tempest Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tempest Therapeutics and other key companies, straight to your email.

About Tempest Therapeutics

Tempest Therapeutics (NASDAQ:TPST) is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells. Additional preclinical programs aim to block key kinases involved in immune suppression, thereby complementing existing checkpoint inhibitors. Tempest has initiated early‐phase clinical studies in North America and Europe, collaborating with academic and industry partners to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with advanced malignancies.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Tempest Therapeutics was established to translate cutting‐edge metabolic and immunological insights into novel oncology treatments. The company’s leadership team combines expertise in drug discovery, clinical development, and regulatory strategy, with decades of experience at both emerging biotechnology firms and large pharmaceutical companies. Tempest is supported by leading life‐science investors and maintains research collaborations to expand its pipeline and accelerate the delivery of new therapies to patients worldwide.

View Tempest Therapeutics Profile